1
|
Hosaka N. Thymus transplantation as immunotherapy for the enhancement and/or correction of T cell function. Med Mol Morphol 2024; 57:155-160. [PMID: 38935299 DOI: 10.1007/s00795-024-00394-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2024] [Accepted: 06/20/2024] [Indexed: 06/28/2024]
Abstract
The thymus is where T cells, among the most important immune cells involved in biological defense and homeostasis, are produced and developed. The thymus plays an important role in the defense against infection and cancer as well as the prevention of autoimmune diseases. However, the thymus gland atrophies with age, which might have pathological functions, and in some circumstances, there is a congenital defect in the thymus. These can be the cause of many diseases related to the dysregulation of T cell functions. Thus, the enhancement and/or normalization of thymic function may lead to protection against and treatment of a wide variety of diseases. Therefore, thymus transplantation is considered a strong candidate for permanent treatment. The status and issues related to thymus transplantation for possible immunotherapy are discussed although it is still at an early stage of development.
Collapse
Affiliation(s)
- Naoki Hosaka
- Department of Pathology, Fuchu Hospital, 1-10-7 Hiko-Cho, Izumi, Osaka, 594-0076, Japan.
- Department of Hygiene and Public Health, Kansai Medical University, 2-5-1 Shin-Machi, Hirakata, Osaka, 573-1010, Japan.
| |
Collapse
|
2
|
Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation. J Immunol Res 2018; 2018:7271097. [PMID: 30057919 PMCID: PMC6051097 DOI: 10.1155/2018/7271097] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 05/10/2018] [Accepted: 05/23/2018] [Indexed: 01/05/2023] Open
Abstract
We recently developed a new allogeneic hematopoietic stem cell transplantation method (allo-HSCT) combined with thymus transplantation (TT) from the same donor (allo-HSCT + TT). This method induces elevated T cell function with mild graft-versus-host disease (GVHD) in comparison to conventional HSCT alone and HSCT + donor lymphocyte infusion (DLI). This new method is effective against several intractable diseases, including malignant tumors, for which conventional treatments are ineffective. Regulatory T (Treg) cells play an important role in the enhanced graft-versus-tumor (GVT) effect and reduction of GVHD, thus leading to longer survival. Replacement and reduction of elevated Treg cells by donor-derived allo-Treg cells from the transplanted thymus may play one of crucial roles in the effect. This review discusses the role of Treg cells in a tumor-bearing mouse model treated with allo-HSCT + TT.
Collapse
|
3
|
Hosaka N. New allogeneic hematopoietic stem cell transplantation method: hematopoietic stem cell transplantation plus thymus transplantation for intractable diseases. Clin Dev Immunol 2013; 2013:545621. [PMID: 23762092 PMCID: PMC3665168 DOI: 10.1155/2013/545621] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 03/17/2013] [Accepted: 04/19/2013] [Indexed: 12/17/2022]
Abstract
Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) has become a valuable strategy for some intractable diseases, a number of problems remain to be resolved. We have developed a new HSCT method, HSCT + thymus transplantation (TT) from the same donor, which induces elevated T cell function with mild graft-versus-host disease (GVHD) in comparison to conventional HSCT alone and HSCT + donor lymphocyte infusion (HSCT + DLI). This new method is effective in the treatment of several intractable diseases and conditions, such as autoimmune diseases in aging, advanced malignant tumors, exposure to supralethal irradiation, multiple organ transplantation from different donors, and type 2 diabetes mellitus, for which conventional methods are ineffective. Our findings suggest that allo-HSCT + TT is preferable to conventional allo-HSCT alone or allo-HSCT + DLI. This method may become a valuable next-generation HSCT technique.
Collapse
Affiliation(s)
- Naoki Hosaka
- Department of Pathology, Kansai Medical University Kori Hospital, 8-45 Korihondori, Neyagawa, Osaka 572-8851, Japan.
| |
Collapse
|
4
|
Zhang Y, Hosaka N, Cui Y, Shi M, Li M, Li Q, Ikehara S. Effects of intrabone marrow-bone marrow transplantation plus adult thymus transplantation on survival of mice bearing leukemia. Stem Cells Dev 2011; 21:1441-8. [PMID: 21861761 DOI: 10.1089/scd.2011.0358] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We recently found that allogeneic intrabone marrow-bone marrow transplantation (IBM-BMT) plus adult thymus transplantation (ATT) from the same donor is effective in mice bearing solid tumors. In the current study, we examined the effects of this strategy on the survival of mice with leukemia. One week after intravenous injection of 1×10(6) leukemic cells (EL-4, H-2(b)) into 8-week-old B6 (H-2(b)) mice, the mice were 8 Gy irradiated and transplanted with 1×10(7) bone marrow cells (BMCs) from 8-week-old BALB/c mice (H-2(d)) by IBM-BMT with or without donor lymphocyte infusion (DLI) or ATT. All the mice without treatment died within 70 days after injection of EL-4. About 40% of those treated with IBM-BMT alone died within 100 days due to tumor relapse. In contrast, those treated with IBM-BMT+DLI or ATT showed the longest survival rate without relapse of leukemia. In addition, the former showed less graft versus host disease (GVHD) than the latter. The mice treated with IBM-BMT+ATT also showed an intermediate percentage of effector memory (EM) and central memory (CM) cells between those treated with BMT alone and those treated with IBM-BMT+DLI. The numbers and functions of T cells increased in those treated with IBM-BMT+ATT with interleukin-2 and interferon-γ production. These results suggest that IBM-BMT+ATT is effective in the treatment of leukemia with strong graft versus leukemia without increased risk of GVHD.
Collapse
Affiliation(s)
- Yuming Zhang
- Department of Pediatrics, Nanfang Hospital, Guangzhou, China
| | | | | | | | | | | | | |
Collapse
|
5
|
Wang Y, Liu J, Xu C, Zhang W, Bai L, Li N, Liu Y, Wang Y, Su Y, Hu D. Bone marrow transplantation combined with mesenchymal stem cells induces immune tolerance without cytotoxic conditioning. J Surg Res 2011; 171:e123-31. [PMID: 21920556 DOI: 10.1016/j.jss.2011.06.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 06/03/2011] [Accepted: 06/09/2011] [Indexed: 01/01/2023]
Abstract
BACKGROUND Transplantation of allogeneic donor bone marrow (BM) into sufficiently conditioned recipients is an effective approach to induce immune tolerance as assessed by mixed chimerism. However, this approach is hampered by the lack of feasible protocols devoid of cytoreductive conditioning. We investigated whether mixed chimerism could be established by intra-bone marrow-bone marrow transplantation (IBM-BMT) combined with bone marrow-derived mesenchymal stem cells (BMSCs) treatment without additional cytoreductive conditioning. MATERIALS AND METHODS The recipient mice (C57BL/6) accepted BMSCs from donor mice (Balb/c) through daily tail vein injection for 4 d followed by IBM-BMT immediately. Full-thickness skin grafts from donor mice as well as from the third party mice (ICR) were transplanted to the dorsum of the recipient mice after the combined IBM-BMT with BMSCs treatment. The immune tolerance was assessed by the survival time of skin allografts. The establishment of mixed chimerism and cytokine expression profile in recipient peripheral blood were determined by flow cytometry and enzyme-linked immunosorbent assay, respectively. RESULTS IBM-BMT combined with BMSCs treatment led to stable mixed chimerism and donor-specific skin graft tolerance. The flow cytometry analysis revealed that recipient mice developed 20%-25% chimerism levels among the myeloid lineage. The skin allografts survived more than 1 y and the hair re-grew normally on the grafts. Cytokine profile showed that IBM-BMT combined with BMSCs treatment prolonged humoral tolerance in recipient chimeras. CONCLUSIONS Our results demonstrate that donor specific immune tolerance can be effectively induced by IBM-BMT combined with BMSCs treatment without any additional cytoreductive recipient treatment. This approach provides a promising allograft transplantation strategy when the donor bone marrow is available.
Collapse
Affiliation(s)
- Yunchuan Wang
- Department of Burns and Cutaneous Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ikehara S. Thymus transplantation for treatment of cancer: lessons from murine models. Expert Rev Clin Immunol 2011; 7:205-11. [PMID: 21426258 DOI: 10.1586/eci.10.100] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
It is well known that tumor-bearing mammals, including humans, show decreased T-cell function due to involution of the thymus. This decrease results in faster tumor growth, susceptibility to infection and reduced life expectancy. Thus, the best strategy to restore T-cell function might be to transplant the thymus from the fetus or newborn. Based on this hypothesis, this article introduces our recent findings using mice and evidence is provided that, in humans, thymus transplantation in conjunction with bone marrow transplantation could become a valuable strategy for suppressing tumor growth, thereby prolonging survival.
Collapse
Affiliation(s)
- Susumu Ikehara
- Department of Stem Cell Disorders, Kansai Medical University, Osaka, Japan.
| |
Collapse
|
7
|
Zhang Y, Hosaka N, Cui Y, Shi M, Ikehara S. Effects of allogeneic hematopoietic stem cell transplantation plus thymus transplantation on malignant tumors: comparison between fetal, newborn, and adult mice. Stem Cells Dev 2010; 20:599-607. [PMID: 20672991 DOI: 10.1089/scd.2010.0230] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
We have recently shown that allogeneic intrabone marrow-bone marrow transplantation + adult thymus transplantation (TT) is effective for hosts with malignant tumors. However, since thymic and hematopoietic cell functions differ with age, the most effective age for such intervention needed to be determined. We performed hematopoietic stem cell transplantation (HSCT) using the intrabone marrow method with or without TT from fetal, newborn, and adult B6 mice (H-2(b)) into BALB/c mice (H-2(d)) bearing Meth-A sarcoma (H-2(d)). The mice treated with all types of HSCT + TT showed more pronounced regression and longer survival than those treated with HSCT alone in all age groups. Those treated with HSCT + TT showed increased numbers of CD4(+) and CD8(+) T cells but decreased numbers of Gr-1/Mac-1 myeloid suppressor cells and decreased percentages of FoxP3 cells in CD4(+) T cells, compared with those treated with HSCT alone. In all mice, those treated with fetal liver cell (as fetal HSCs) transplantation + fetal TT or with newborn liver cell (as newborn HSCs) transplantation (NLT) + newborn TT (NTT) showed the most regression, and the latter showed the longest survival. The number of Gr-1/Mac-1 cells was the lowest, whereas the percentage of CD62L(-)CD44(+) effector memory T cells and the production of interferon γ (IFN-γ) were highest in the mice treated with NLT + NTT. These findings indicate that, at any age, HSCT + TT is more effective against cancer than HSCT alone and that NLT + NTT is most effective.
Collapse
Affiliation(s)
- Yuming Zhang
- First Department of Pathology, Kansai Medical University, Osaka, Japan
| | | | | | | | | |
Collapse
|
8
|
Cui Y, Nakamura S, Shi M, Feng W, Cui W, Guo K, Zhang Y, Ikehara S. A successful haploidentical bone marrow transplantation method in rabbits: perfusion method plus intra-bone marrow-bone marrow transplantation. Transpl Immunol 2010; 24:33-9. [PMID: 20624463 DOI: 10.1016/j.trim.2010.06.014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2009] [Revised: 06/25/2010] [Accepted: 06/28/2010] [Indexed: 11/17/2022]
Abstract
Graft versus host disease (GVHD), rejection, delayed immune reconstitution and infections have been significant hurdles to haploidentical BMT. In order to improve the outcome of the current haploidentical-related BMT, we performed a novel BMT method consisting of the perfusion method (PM) plus intra-bone marrow-bone marrow transplantation (IBM-BMT) in a rabbit model. The percentages of T cells in BMCs harvested by the PM and the conventional aspiration method (AM) were 6% and 14%, respectively (p<0.01). Conversely, the CFU-C counts of BMCs in the PM group were significantly higher than those in the AM group. When the BMCs were transplanted into lethally irradiated offspring rabbits by IBM-BMT, hemopoietic recovery in the PM group was faster than in the AM group. The cumulative incidence of acute GVHD was 25% in the PM group versus 75% in the AM group (p<0.05). In addition, the survival rate was 75% in the PM group versus 33% in the AM group (p<0.05). Thus, the new method is able to provide rapid hemopoiesis, reduce the cumulative incidence of acute GVHD, and achieve a higher survival rate. This novel strategy paves the way for new dimensions in haploidentical BMT.
Collapse
Affiliation(s)
- Yunze Cui
- Department of Stem Cell Disorders, Kansai Medical University, Moriguchi City, Osaka, Japan
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Hosaka N, Cui W, Zhang Y, Takaki T, Inaba M, Ikehara S. Prolonged survival in mice with advanced tumors treated with syngeneic or allogeneic intra-bone marrow-bone marrow transplantation plus fetal thymus transplantation. Cancer Immunol Immunother 2010; 59:1121-30. [PMID: 20229083 PMCID: PMC11030866 DOI: 10.1007/s00262-010-0840-2] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2009] [Accepted: 02/23/2010] [Indexed: 12/20/2022]
Abstract
Thymic function decreases in line with tumor progression in patients with cancer, resulting in immunodeficiency and a poor prognosis. In the present study, we attempted to restore thymic function by BALB/c (H-2(d)) syngeneic (Syn), or B6 (H-2(b)) allogeneic (Allo) bone marrow transplantation (BMT) using intra-bone marrow-bone marrow transplantation (IBM-BMT) plus Syn-, Allo- or C3H (H-2(k)) 3rd-party fetal thymus transplantation (TT). Although the BALB/c mice with advanced tumors (Meth-A sarcoma; H-2(d), >4 cm(2)) treated with either Syn- or Allo-BMT alone showed a slight improvement in survival compared with non-treated controls, the mice treated with BMT + TT showed a longer survival. The mice treated with Allo-BMT + Allo-TT or 3rd-party TT showed the longest survival. Interestingly, although there was no difference in main tumor size among the BMT groups, lung metastasis was significantly inhibited by Allo-BMT + Allo-TT or 3rd-party TT. Numbers of CD4(+) and CD8(+) T cells, Con A response, and IFN-gamma production increased significantly, whereas number of Gr-1(+)/CD11b(+) myeloid suppressor cells and the percentage of FoxP3(+) cells in CD4(+) T cells significantly decreased in these mice. Furthermore, there was a positive correlation between survival days and the number of T cells or T cell function, while there was a negative correlation between survival days and lung metastasis, the number of Gr-1(+)/CD11b(+) cells, or the percentage of FoxP3(+) cells. These results suggest that BMT + TT, particularly Allo-BMT + Allo-TT or 3rd-party TT, is most effective in prolonging survival as a result of the restoration of T cell function in hosts with advanced tumors.
Collapse
MESH Headings
- Animals
- Bone Marrow Transplantation/methods
- CD11b Antigen/immunology
- Cell Line, Tumor
- Cytokines/metabolism
- Female
- Fetal Tissue Transplantation/methods
- Flow Cytometry
- Forkhead Transcription Factors/metabolism
- Interferon-gamma/metabolism
- Lung Neoplasms/immunology
- Lung Neoplasms/secondary
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C3H
- Mice, Inbred C57BL
- Neoplasms, Experimental/immunology
- Neoplasms, Experimental/pathology
- Neoplasms, Experimental/surgery
- Receptors, Chemokine/immunology
- Survival Analysis
- T-Lymphocytes/cytology
- T-Lymphocytes/immunology
- T-Lymphocytes/metabolism
- Thymus Gland/embryology
- Thymus Gland/transplantation
- Time Factors
- Transplantation, Homologous
- Transplantation, Isogeneic
Collapse
Affiliation(s)
- Naoki Hosaka
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
| | - Wenhao Cui
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
| | - Yuming Zhang
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
- Department of Pediatrics, Nanfang Hospital, Guangzhou, 510515 China
| | - Takashi Takaki
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
| | - Muneo Inaba
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
| | - Susumu Ikehara
- First Department of Pathology, Kansai Medical University, 10-15 Fumizono-cho, Moriguchi, Osaka 570-8506 Japan
| |
Collapse
|
10
|
Miyake T, Hosaka N, Cui W, Nishida T, Takaki T, Inaba M, Kamiyama Y, Ikehara S. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects. Immunology 2009; 126:552-64. [PMID: 18778285 PMCID: PMC2673367 DOI: 10.1111/j.1365-2567.2008.02920.x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2008] [Revised: 06/23/2008] [Accepted: 07/11/2008] [Indexed: 01/04/2023] Open
Abstract
Although allogeneic bone marrow transplantation (BMT) plus donor lymphocyte infusion (DLI) is performed for solid tumours to enhance graft-versus-tumour (GVT) effects, a graft-versus-host reaction (GVHR) is also elicited. We carried out intra-bone marrow-bone marrow transplantation (IBM-BMT) plus adult thymus transplantation (ATT) from the same donor to supply alloreactive T cells continually. Normal mice treated with IBM-BMT + ATT survived for a long time with high donor-derived thymopoiesis and mild GVHR. The percentage of CD4(+) FoxP3(+) regulatory T cells in the spleen of the mice treated with IBM-BMT + ATT was lower than in normal B6 mice or mice treated with IBM-BMT alone, but higher than in mice treated with IBM-BMT + DLI; the mice treated with IBM-BMT + DLI showed severe GVHR. In tumour-bearing mice, tumour growth was more strongly inhibited by IBM-BMT + ATT than by IBM-BMT alone. Mice treated with IBM-BMT + a high dose of DLI also showed tumour regression comparable to that of mice treated with IBM-BMT + ATT but died early of GVHD. By contrast, mice treated with IBM-BMT + a low dose of DLI showed longer survival but less tumour regression than the mice treated with IBM-BMT + ATT. Histologically, significant numbers of CD8(+) T cells were found to have infiltrated the tumour in the mice treated with IBM-BMT + ATT. The number of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end-labelling (TUNEL)-positive apoptotic tumour cells also significantly increased in the mice treated with IBM-BMT + ATT. Allogeneic IBM-BMT + ATT thus can induce high thymopoiesis, preserving strong GVT effects without severe GVHR.
Collapse
Affiliation(s)
- Takashi Miyake
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
- Department of Surgery, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Naoki Hosaka
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Wenhao Cui
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Teruhisa Nishida
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Takashi Takaki
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Muneo Inaba
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Yasuo Kamiyama
- Department of Surgery, Kansai Medical UniversityMoriguchi, Osaka, Japan
| | - Susumu Ikehara
- First Department of Pathology, Kansai Medical UniversityMoriguchi, Osaka, Japan
| |
Collapse
|
11
|
Allogeneic intra-BM-BMT plus adult thymus transplantation from same donor has benefits for long-term survival even after sublethal irradiation or low-dose BM cell injection. Bone Marrow Transplant 2008; 43:829-37. [DOI: 10.1038/bmt.2008.396] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|